Tanya Dorff, MD, Associate Professor in the Department of Medical Oncology & Therapeutics Research, and Section Chief of the Genitourinary Disease Program, City of Hope Comprehensive Cancer Center, shares the barriers to utilizing PARP inhibitors plus androgen receptor-targeted agents in the castration-sensitive or upfront prostate cancer settings.
View Dr. Dorff’s other comments on treatment for prostate cancer, including PROpel and MAGNITUDE Trials for mCRPC and Combination Versus Sequential Therapy for mCRPC.